Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ischaemic heart disease, infection, and treatment of infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Pernille G Thrane
  • Steen D Kristensen
  • Kevin K W Olesen
  • Leif S Mortensen
  • Hans Erik Bøtker
  • Leif Thuesen
  • Henrik S Hansen
  • Ulrik Abildgaard
  • Thomas Engstrøm
  • Henning R Andersen
  • Michael Maeng
View graph of relations

AIMS: The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial found that interhospital transport to primary percutaneous coronary intervention (pPCI) was superior to fibrinolysis at the local hospital in patients with ST-segment elevation myocardial infarction (STEMI) at 30 days. The present study investigates the 16-year cardiovascular outcomes.

METHODS AND RESULTS: We randomized 1572 STEMI patients to pPCI or fibrinolysis at 24 referral hospitals and 5 invasive centres in Denmark. Patients randomized to pPCI at referral hospitals were immediately transported to the nearest invasive centre. The main endpoint of the current study was a composite of death or rehospitalization for myocardial infarction (MI). Outcome information beyond 3 years was obtained through Danish health registries. After 16 years, pPCI-treated patients had a sustained lower rate of composite endpoint compared to patients treated with fibrinolysis in the overall cohort [58.7% vs. 62.3%; hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.98], and among patients transported for pPCI (58.7% vs. 64.1%; HR 0.82, 95% CI 0.71-0.96). No difference in all-cause mortality was found, but cardiac mortality was reduced by an absolute of 4.4% in favour of pPCI (18.3% vs. 22.7%; HR 0.78, 95% CI 0.63-0.98). pPCI postponed a main event with 12.3 months in average compared to fibrinolysis (95% CI 5.0-19.5).

CONCLUSION: The benefit of pPCI over fibrinolysis was maintained at 16-year follow-up. pPCI reduced the composite endpoint of death or rehospitalization for MI, reduced cardiac mortality, and delayed average time to a main event by approximately 1 year.

Original languageEnglish
JournalEuropean Heart Journal
Volume41
Issue number7
Pages (from-to)847-854
Number of pages8
ISSN0195-668X
DOIs
Publication statusPublished - 14 Feb 2020

ID: 59125709